Influence of the medical treatment schedule in new diagnoses patients with heart failure and reduced ejection fraction

Esteban-Fernández, Alberto; Gómez-Otero, Inés; López-Fernández, Silvia; Santamarta, Miguel Rodríguez; Pastor-Pérez, Francisco J.; Fluvià-Brugués, Paula; Pérez-Rivera, José-Ángel; López López, Andrea; García-Pinilla, José Manuel; Palomas, Juan Luis Bonilla; Bonet, Luis Almenar; Cobo-Marcos, Marta; Mateo, Virgilio Martínez; Llergo, Javier Torres; Fernández, Vanesa Alonso; Vives, Cristina Goena; de Juan Bagudá, Javier; Benedicto, Alba Maestro; de Polavieja, José Ignacio Morgado; Solla-Ruiz, Itziar; Solé-González, Eduard; Cardona, Montserrat; Olaetxea, Javier Rekondo; Cortés, Carolina Ortiz; Dosantos, Victor Martínez; López, Antonio Gámez; Amao, Elvis; Sánchez, Borja Casas; Torres, Edgardo Alania; Carrillo, Víctor Gómez; García-Fuertes, Daniel; Ridocci-Soriano, Francisco; ,; Arana-Achaga, Xabier; Jiménez, Francisco José Bermúdez; Marcos, Marta Cobo; Álvarez, Concepción Cruzado; Jiménez, Juan F. Delgado; Trenado, Víctor Donoso; Rozas, Inmaculada Fernández; Fort, Aleix; García, Belén; Carmena, María Dolores García-Cosío; Rubio, Clara Jiménez; Martínez, Laura Jordán; Reynolds, Bernardo Lanza; López-Azor, Juan Carlos; Vilella, Raquel López; Bahamonde, Ainara Lozano; Clement, Irene Marco; Sabastia, Elisabet Mena; Villar, María Molina; Villota, Julio Nuñez; Merino, Pedro Agustín Pájaro; Cabeza, Alejandro Pérez; Martínez, Montserrat Puga; Mezcua, Ainhoa Robles; Corral, Ester Sánchez; Muñoz, Enrique Sánchez; Aumente, José María Segura; Torrecilla, Estefanía; Benito, Iñaki Villanueva

doi:10.1007/s00392-023-02241-0

Clin Res Cardiol

2023

DOI: 10.1007/s00392-023-02241-0

|View full text |Cite

Influence of the medical treatment schedule in new diagnoses patients with heart failure and reduced ejection fraction

Alberto Esteban-Fernández,

Inés Gómez-Otero,

Silvia López-Fernández

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Annual evolution of the prescription of drugs with prognostic implications in acute decompensated heart failure with reduced ejection fraction

López-Vilella,

DonosoTrenado,

Guerrero Cervera

et al. 2024

BMC Cardiovasc Disord

View full text Add to dashboard Cite

Background Quadruple therapy (renin angiotensin system inhibitors, beta-blockers, mineralocorticoid receptor antagonists and sodium/glucose cotransporter type 2 inhibitors [SGLT2i]) has become the current prognostic modifying treatment for heart failure (HF) with reduced ejection fraction (HFrEF). This study aimed to analyse the prescription´s evolution of this combination therapy, the analysis of each pharmacological group and the differences according to HF subgroups. Methods Retrospective analysis of consecutive patients admitted for cardiac decompensation. Inclusion period: from 1-1-2020 to 12-31-2022. Patients with left ventricular ejection fraction > 40% and deceased during admission were excluded. Finally, 602 patients were included. These were divided into: (a) de novo HF without previous heart disease (n:108), (b) de novo with previous heart disease (n:107), and (c) non-de novo (n:387). Results Over the study time, all pharmacological groups experienced an increase in drugs prescription (p < 0.001). The group with the largest prescription rate increase was SGLT2i (2020:20%, 2021:42.9%, 2022:70.4%; mean increase 47.2%). The discharge rate prescription of quadruple therapy increased progressively (2020:7.4%, 2021:21.1%, 2022:32.5%; mean increase 21.9%). The subgroup with the highest combined prescription in 2022 was de novo with previous heart disease (43.9%). Conclusion The pharmacological group with the largest prescription´s rate increase was SGLT2i. The percentage of patients discharged on quadruple therapy has progressed significantly in recent years, although it remains low. The most optimised subgroup at discharge was that of de novo HF with previous heart disease.

show abstract

Annual evolution of the prescription of drugs with prognostic implications in acute decompensated heart failure with reduced ejection fraction

López-Vilella,

DonosoTrenado,

Guerrero Cervera

et al. 2024

BMC Cardiovasc Disord

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Influence of the medical treatment schedule in new diagnoses patients with heart failure and reduced ejection fraction

Cited by 1 publication

References 35 publications

Annual evolution of the prescription of drugs with prognostic implications in acute decompensated heart failure with reduced ejection fraction

Annual evolution of the prescription of drugs with prognostic implications in acute decompensated heart failure with reduced ejection fraction

Contact Info

Product

Resources

About